How I Made $5000 in the Stock Market

Trump, Markets Got the Fed Rate Cut They Wanted. Why Both May Become Disappointed.

Sep 18, 2025 06:45:00 -0400 | #Markets #The Barron's Daily

Federal Reserve Chair Jerome Powell (Chip Somodevilla/Getty Images)

President Donald Trump had better things to do on Wednesday than criticize Federal Reserve Chair Jerome Powell—the U.S. leader was attending a lavish U.K. state banquet hosted by King Charles III.

But as the 160 guests at Windsor Castle tucked into their watercress panna cotta and chicken ballotine, investors also had plenty to digest following the central bank’s first interest-rate cut of 2025.

The Fed lowered borrowing costs by a quarter of a point, which had been widely expected. Officials also forecast that rates will fall by another 50 basis points over the course of this year, which likely translates to further reductions in October and December.

Powell called the decision a “risk-management cut,” signaling that the central bank was moving to prop up the faltering labor market but was still trying to tame inflation. Wall Street didn’t know what to make of that, as stocks seesawed before finishing the session a touch lower.

Eleven of the 12 voting members of the Federal Open Market Committee backed a quarter-point cut. Stephen Miran, fresh off his Senate confirmation, favored a half-point reduction —and his personal dot plot signaled he will support jumbo-sized cuts again at the October and December meetings.

It offers investors two different visions for what the Fed may look like when Powell’s term as Fed chair ends in May.

Trump could nominate a replacement like Fed Gov. Christopher Waller, who has signaled he would stay dovish but try to build a consensus on monetary policy. Or he could pick a staunch ally like Miran, who would likely favor aggressive rate cuts even if that triggered a flare-up in inflation.

Both scenarios will likely lead to lower interest rates, which will support the bull market.

But Powell’s “risk management” comment is a reminder that the central bank will only cut in the months ahead if the data suggest it’s wise to do so. Investors shouldn’t get too carried away or they—and Trump—may end up royally disappointed.

George Glover

***

The Fed Cut Rates As Expected. Here’s What’s Next.

The Federal Reserve has cut interest rates for the first time in nine months, signaling concerns about a weakening labor market. As was widely expected, the policymakers cut the benchmark rate by a quarter of a point, with only one official seeking more. There are likely more moves to come.

What’s Next: Fed Chair Jerome Powell, a target of President Donald Trump’s repeated criticism for not cutting rates sooner, doubled down on the institution’s commitment to steer clear of politics. “We’re strongly committed to maintaining our independence and beyond that, I really don’t have anything to share.”

Sabrina Escobar

***

Job Gains Slowing and Fed Sees More Downside Risks to Unemployment

Fed policymakers and Chair Powell both noted that job gains are slowing and unemployment is climbing, among other challenges to the U.S. labor market that complicate the central bank’s dual mandate to strive for both maximum employment and price stability.

What’s Next: Despite signs that the labor market is cooling, Fed officials kept their unemployment rate forecasts unchanged for the rest of the year. Unemployment has been drifting higher, rising to 4.3% in August, the highest since 2021. Fed officials forecast unemployment to rise to 4.5% by the end of 2025.

Connor Smith, Megan Leonhardt, and Janet H. Cho

***

Lilly and Novo Nordisk Press Ahead in Weight-Loss Pill Race

Drugmakers at the top of the weight-loss game— Eli Lilly with its Zepbound and Novo Nordisk with its Wegovy—are racing to offer a pill alternative that’s as effective as their blockbuster injectables, and new data are emerging that they are making progress.

What’s Next: Kenneth Custer, president of Lilly Cardiometabolic Health, said the trial results, combined with the drug’s once-daily oral dosing and broad scalability reinforce its potential as a foundational treatment for Type 2 diabetes. The late-stage results pave the way for Lilly to start regulatory submissions.

Josh Nathan-Kazis and Janet H. Cho

***

Walmart Pushes to Become a Leader In Agentic AI

Walmart doesn’t immediately come to mind as belonging in the same sentence with the term artificial intelligence, but the retailing giant could be poised to join the early leaders in agentic AI while rivals from Amazon to Target are fighting to stay ahead of the trend.

What’s Next: Sparky is one of four agentic AI tools Walmart is preparing as it aims to drive retail sales through its online store. Walmart is aiming for e-commerce sales to make up 50% of its total sales in five years.

Mackenzie Tatananni and Liz Moyer

***

—Newsletter edited by Liz Moyer, Patrick O’Donnell, Callum Keown